contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


bbs-bioactive-bone-substitutes-plc-the-finnish-financial-supervisory-authority-has-imposed-a-penalty-payment-on-a-two-current-and-one-former-member-of-companys-board-of-directors

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Virksomheden har ikke råd til at spilde en eneste euro. Alt, der giver penge, vil

De kommer ikke til salg, de sælges med ejendommen og ender derfor på den lokale genbrugsstation. Boet sælger varer for at få penge i kassen. Jeg synes, det er indlysende, at en specialfremstillet produktionslinje kun er værdifuld for bestilleren.

Jeg venter på, at de meget roste, egenudviklede produktionsmaskiner og -linjer kommer til salg. Indtil videre har man jo kun set bulkmaskiner og -udstyr.

Konkursboet ser ud til at sælge resterne igen, denne gang her: https://realisointihuutokauppa.fi/?filter=suosituimmat&city=Reisjärvi&konkurssipesa=BBS-Bioactive%20Bone%20Substitutes%20Oyj%20konkurssipesä%20(0866451-4) Kan bobehandlingen følges via en offentlig tjeneste, eller skrider sagen frem ‘engang og til jul’ i det tempo, som advokatfirmaet Fennoa er interesseret i at fremme den?

Efter du har solgt aktierne eller senest efter kurators endelige opgørelse, er der tale om kapitaltab. Blot at blive afnoteret er ikke nok, som man så med Talvivaara, da selskabet i årevis hang som et unoteret ‘Ahtium’ og nægtede at gå konkurs, så tabene kunne heller ikke fratrækkes.  Jeg har investeringer i unoterede virksomheder. Kan jeg fratrække det investerede beløb fra min kapitalindkomst, hvis en unoteret virksomhed går konkurs? Skal jeg i så fald skaffe en form for bevis for konkursen? Anskaffelsesprisen fremgår af aktionæroverenskomsten. Skattejurist Miika Härkönen svarer: Et endeligt værditab på et værdipapir som følge af konkurs kan fratrækkes som kapitaltab. Der skal foreligge pålidelig dokumentation for anskaffelsesprisen. Kapitaltab opstår i det skatteår, hvor værditabet er endeligt. Dette sker, når kurator meddeler, at der ikke vil blive udbetalt udlodning, eller når konkursboets endelige opgørelse foretages. Hvis et aktieselskabs konkurs bortfalder på grund af manglende midler, anses aktiernes værdi for endeligt tabt, når selskabet slettes fra handelsregisteret. Kapitaltab kan fratrækkes kapitalindkomsten i skatteåret og de fem efterfølgende år. Skattejuristens svar blev offentliggjort i Taloustaito2 den 3.5.2022.             veronmaksajat.fi              Listaamaton yritys menee konkurssin – voinko vähentää tappion pääomatuloistani?    Minulla on sijoituksia listaamattomissa yrityksissä. Voinko vähentää sijoitetun summan pääomatuloistani, jos listaamaton yritys menee konkurssiin? Pitääkö minun tällöin hankkia konkurssista joku todistus? Hankintahinta ilmenee osakassopimuksesta....

Hvad får antallet af ejere til at svinge? Der var kommet tre nye ejere i oktober. Redigering: Udenlandsk ejerskab steg 1,91%→ 1,92%.

BBS-Bioactive Bone Substitutes

BBS-Bioactive Bone Substitutes Plc | Company Release | January 31, 2025 at 16:30:00 EETBBS-Bioactive Bone Substitutes Plc: The Finnish Financial Supervisory Authority has imposed a penalty payment...

<div class="mfn-header mfn-header-finland"><p>BBS-Bioactive Bone Substitutes Plc | Company Release | January 31, 2025 at 16:30:00 EET</p></div><div class="mfn-preamble"><p><strong>BBS-Bioactive Bone Substitutes Plc: The Finnish Financial Supervisory Authority has imposed a penalty payment on a two current and one former member of Company’s Board of Directors</strong></p></div><div class="mfn-body"><p>The Finnish Financial Supervisory Authority (the "FIN-FSA") has imposed a penalty payment of EUR 4,000 on Pekka Jalovaara and EUR 5,000 on Jarmo Halonen, current members of BBS-Bioactive Bone Substitute’s Board of Directors, and payment of EUR 9,000 on Ahti Paananen, a former member of BBS-Bioactive Bone Substitute’s Board of Directors, for discharging managerial responsibilities for the late notifications of transactions in BBS-Bioactive Bone Substitute’s shares made in their own account.</p><p>The decision of the FIN-FSA is not yet legally binding and can be appealed by the individuals.</p></div><div class="mfn-footer mfn-contacts mfn-68bef424ac99"><p><strong class="mfn-heading-1">For more information, please contact:</strong><br>Juliusz Rakowski, CEO<br>+358 50 448 5132<br><a rel="noopener" href="mailto:juliusz.rakowski@bbs-artebone.fi">juliusz.rakowski@bbs-artebone.fi</a></p></div><div class="mfn-footer mfn-1586e9e67a6a"><p><strong class="mfn-heading-1">Certified Advisor:</strong><br>Nordic Certified Adviser AB,<br>+46 70 551 67 29,<br><a rel="noopener" href="mailto:info@certifiedadviser.se">info@certifiedadviser.se</a></p></div><div class="mfn-footer mfn-67c8b2406f27"><p><strong class="mfn-heading-1">Distribution</strong><br>Nasdaq Helsinki<br><a rel="noopener" href="https://www.globenewswire.com/Tracker?data=dTX6KuwjXtC9yntip5ccELHgyMLbOC8p_qwAud8wR_OwuwTNIX6JB9T-9u2qDUKExAyUvAxRxfba9dWlnEvLjYC4hCeAo5EaIC_bkSh7hyM33b3gIm16ZVkdAzBgSsOw">https://www.bbs-artebone.fi/</a></p></div><div class="mfn-footer mfn-about mfn-838eb0731ac0"><p><strong class="mfn-heading-1">BBS in brief</strong><br><em>BBS -Bioactive Bone Substitutes Plc is an orthobiology company that started its operations in 2003. We have developed a new product for the treatment of complex bone fractures and bone healing issues. Our goal is to provide next-generation medical products for the treatment of bone injuries in orthopedic surgery. In the pharmaceutical industry, the development and research work require perseverance and courage to innovate. We have a track record of over 20 years in this field. Our company is characterized by expertise, innovation, and dedicated employees who are passionate about their work. Our first developed product, ARTEBONE® Paste, is in the final stages of the CE marking process to enable its commercialization in the EU market. We are based in Oulu with a medical manufacturing facility in Reisjärvi, holding a manufacturing license. The company's headquarters are in Oulu, and we employ over 20 people.</em><em><br></em><br><em>BBS has been listed on Nasdaq First North Growth Market Finland since February 2018.</em><em><br></em><br><em>More information: </em><em><a rel="noopener" href="http://www.bbs-artebone.fi/">www.bbs-artebone.fi</a></em></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/1803d8f9-aed0-4119-ad73-59ae7c7286a9/bbs-bioactive-bone-substitutes-plc-the-finnish-financial-supervisory-authority-has-imposed-a-penalty-payment-on-a-two-current-and-one-former-member-of-companys-board-of-directors.pdf" class="mfn-generated mfn-primary">BBS-Bioactive Bone Substitutes Plc: The Finnish Financial Supervisory Authority has imposed a penalty payment on a two current and one former member of Company’s Board of Directors</a></p></div>

BBS-Bioactive Bone Substitutes Plc: The Finnish Financial Supervisory Authority has imposed a penalty payment on a two current and one former member of Company’s Board of Directors